Drugs / BG8962
BG8962
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000721 | ? → Mar 1991 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG8962 | “Whenever the natural sequence molecule (currently under study in this protocol) is referred to, it is called BG8962 or rCD4.” NCT00000721 ↗ |
| Known as | rCD4 | “Whenever the natural sequence molecule (currently under study in this protocol) is referred to, it is called BG8962 or rCD4.” NCT00000721 ↗ |
| Known as | recombinant soluble CD4 | “Biogen's original sequence recombinant soluble CD4 and Biogen's natural sequence recombinant soluble CD4 have both been referred to as recombinant soluble CD4 (rsCD4).” NCT00000721 ↗ |
| Action | Inhibit | “rCD4 binds to HIV and reduces its ability to enter the cell, thus inhibiting its reproduction.” NCT00000721 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant soluble CD4 protein (rCD4) is a drug that has been produced by genetic engineering techniques.” NCT00000721 ↗ |
| Route | Intramuscular | “administered by intramuscular and subcutaneous routes” NCT00000721 ↗ |
| Route | Subcutaneous | “administered by intramuscular and subcutaneous routes” NCT00000721 ↗ |